Abstract

PCN176 - Amnog Benefit Assessment for Oncologic and Orphan Drugs in Germany – Implications for Price Discounts

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
PDG62 Outcomes of Benefit Reassessments of Medicinal Products in Germany after Expiry of the Limitation of G-BA Resolution
L Kleinesudeik ... M.P Schoenermark
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 23
L Kleinesudeik, et. al.L Kleinesudeik ... M.P Schoenermark
01 Dec 2020
PRO94 Outcomes of Benefit Reassessments of Orphan Drugs in Germany after Exceedance of the 50-Million-EURO Revenue Threshold
L Frick ... M.P Schoenermark
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 23
L Frick, et. al.L Frick ... M.P Schoenermark
01 Dec 2020
PSY148 - Price Negotiations for Orphan Drugs in Germany
T Ecker ... M Campion
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 19
T Ecker, et. al.T Ecker ... M Campion
31 Oct 2016
PHP137 - REIMBURSEMENT OF ORPHAN DRUGS UNDER EARLY BENEFIT ASSESMENT IN GERMANY
T Ecker ... D Bot
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 19
T Ecker, et. al.T Ecker ... D Bot
01 May 2016
View more papers

More From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Paper Title
Journal
Date
Author
The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set
-
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
--
21 Jun 2024
Market entry agreements for innovative pharmaceuticals subject to indication broadening: a case study for pembrolizumab in the Netherlands.
Renaud J S D Heine ... Carin A Uyl-De Groot
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
Renaud J S D Heine, et. al.Renaud J S D Heine ... Carin A Uyl-De Groot
21 Jun 2024
MSR99 A Stacked Ensemble Approach for Building Composite Measure Models in Healthcare
P Shi ... S Zhang
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 27
P Shi, et. al.P Shi ... S Zhang
15 Jun 2024
EE98 A Theory-Based Framework to Incorporate Health Equity in Economic Assessments
S Subramanian ... S Hoover
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 27
S Subramanian, et. al.S Subramanian ... S Hoover
15 Jun 2024
View more papers